Global Immune Checkpoint Inhibitors Market Growth 2024-2030

2024

Global Immune Checkpoint Inhibitors Market Growth 2024-2030

Name: Global Immune Checkpoint Inhibitors Market Growth 2024-2030
Brand: Bonafide Research
SKU: 95001287
Price: 3450 USD
Availability: InStock
Rating: 5 (13.95 reviews)

Immune Checkpoint Inhibitors market size was valued at US$ 12.27 billion in 2024, with increasing demand in cancer immunotherapy and related treatments.

Bonafide Trust
17-09-2024
Pages : 92
Figures : 89
Tables : 122
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global immune checkpoint inhibitors (ICI) market has experienced remarkable growth over the past decade, primarily driven by the increasing demand for advanced cancer therapies. Immune checkpoint inhibitors are a class of drugs that work by blocking the inhibitory signals in the immune system, thereby allowing the body’s natural immune response to fight cancer cells more effectively. These therapies have revolutionized cancer treatment, particularly for various cancers such as melanoma, lung cancer, and non-Hodgkin lymphoma, among others. The ability of ICIs to reawaken a patient’s immune system to recognize and attack cancerous cells has been a breakthrough in immuno-oncology. The efficacy of immune checkpoint inhibitors in extending the survival of patients with cancers previously considered untreatable has led to increased research and development in this area. Additionally, the significant success of drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy), which target PD-1, PD-L1, and CTLA-4 pathways, has fueled market growth. These therapies have been approved for a wide range of cancer indications and continue to show promise in clinical trials for other cancers, making them a vital part of modern oncology treatment regimens. With ongoing advancements in the development of combination therapies, where immune checkpoint inhibitors are used alongside other treatment modalities, the market for immune checkpoint inhibitors is poised for continued expansion. The increasing number of patients seeking targeted and personalized cancer therapies, as well as the growing healthcare infrastructure and increasing healthcare spending globally, are key factors contributing to the growth of the immune checkpoint inhibitors market.

According to Publisher, the global Immune Checkpoint Inhibitors market size was valued at US$ 12270 million in 2024. With growing demand in downstream market, the Immune Checkpoint Inhibitors is forecast to a readjusted size of US$ 36140 million by 2030 with a CAGR of 16.7% during review period. North America holds the largest share of the global immune checkpoint inhibitors market, driven by the presence of major pharmaceutical companies, extensive healthcare infrastructure, and a high demand for cancer treatments. The United States, in particular, has witnessed rapid adoption of immune checkpoint inhibitors due to the approval of multiple drugs by the Food and Drug Administration (FDA), making these therapies more accessible to cancer patients. Additionally, the country’s strong focus on research and clinical trials has accelerated the development and approval of new immune checkpoint inhibitors for various cancer types. Europe follows closely in terms of market share, with increasing investments in immuno-oncology research and development. The European market is also benefiting from the growing number of cancer patients, as well as an increasing emphasis on early detection and personalized cancer treatments. The Asia Pacific region is emerging as a key market for immune checkpoint inhibitors, driven by the rapid growth of healthcare infrastructure, rising healthcare expenditures, and an increasing burden of cancer cases. Countries such as Japan, China, and India have seen significant growth in the adoption of immune checkpoint inhibitors due to their expanding healthcare access and government support for cancer treatment initiatives. The rising awareness about immuno-oncology therapies and the increasing availability of these treatments are key drivers of market growth in this region. Furthermore, the market in Latin America and the Middle East is gradually gaining traction, with improving healthcare infrastructure and increasing access to innovative therapies, further fueling the demand for immune checkpoint inhibitors. As global healthcare systems continue to evolve and improve access to cutting-edge cancer therapies, the market for immune checkpoint inhibitors is expected to expand substantially.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The immune checkpoint inhibitors market is primarily segmented by the types of inhibitors used in cancer treatment, with the most prominent categories being PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors. Among these, PD-1 inhibitors have gained the most widespread use due to their effectiveness in treating various cancers, including non-small cell lung cancer, melanoma, and head and neck cancers. Pembrolizumab (Keytruda) and nivolumab (Opdivo) are the leading drugs in this category, showing remarkable success in clinical trials and securing approvals for multiple indications. PD-L1 inhibitors, such as atezolizumab (Tecentriq) and durvalumab (Imfinzi), are another key class of immune checkpoint inhibitors, acting on the PD-L1 pathway to enhance immune system activity against tumors. These drugs have also been approved for various cancers, including bladder cancer and non-small cell lung cancer, and continue to show promise in clinical studies for additional indications. CTLA-4 inhibitors, such as ipilimumab (Yervoy), were among the first immune checkpoint inhibitors to be approved for use in cancer treatment. They are often used in combination with PD-1 or PD-L1 inhibitors to enhance therapeutic efficacy, particularly in cancers like melanoma. The combination of different checkpoint inhibitors is becoming increasingly popular as it has shown better clinical outcomes compared to monotherapy in several cancer types. This trend toward combination therapies is expected to drive further innovation and market growth. Additionally, researchers are investigating other immune checkpoint inhibitors targeting various pathways, such as LAG-3, TIM-3, and TIGIT, which could open up new avenues for treatment and further diversify the product offerings in the market.

The immune checkpoint inhibitors market is also segmented by the different cancer types treated with these therapies, with notable applications in melanoma, lung cancer, breast cancer, prostate cancer, and hematological malignancies. Lung cancer, particularly non-small cell lung cancer (NSCLC), holds a significant share of the market due to the high incidence of the disease and the effectiveness of immune checkpoint inhibitors in treating advanced-stage NSCLC. Drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have been shown to significantly improve survival rates for lung cancer patients, making them the standard of care for advanced stages of the disease. Melanoma, another key cancer type in the immune checkpoint inhibitors market, has also seen remarkable improvements in patient outcomes due to the introduction of checkpoint inhibitors. Both CTLA-4 inhibitors and PD-1 inhibitors have demonstrated efficacy in treating melanoma, particularly in cases with advanced or metastatic disease. Breast cancer and prostate cancer are emerging as promising areas for the application of immune checkpoint inhibitors, with ongoing clinical trials investigating their effectiveness in these cancer types. The success of immune checkpoint inhibitors in hematological malignancies such as non-Hodgkin lymphoma and Hodgkin lymphoma has further expanded their market reach, offering patients a new avenue for treatment where traditional therapies had limited efficacy. The growing number of cancer cases worldwide, coupled with the increasing adoption of immuno-oncology therapies, is expected to drive the demand for immune checkpoint inhibitors across these and other cancer types. The ability of immune checkpoint inhibitors to provide long-term remission and improved survival rates continues to position them as a critical component in the treatment of a broad range of cancers, further fueling their market growth globally.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Immune Checkpoint Inhibitors Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Immune Checkpoint Inhibitors by Country/Region, 2019, 2023 & 2030
2.2 Immune Checkpoint Inhibitors Segment by Type
2.2.1 PD-1/PD-L1
2.2.2 CTLA-4
2.3 Immune Checkpoint Inhibitors Sales by Type
2.3.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2024)
2.3.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Type (2019-2024)
2.3.3 Global Immune Checkpoint Inhibitors Sale Price by Type (2019-2024)
2.4 Immune Checkpoint Inhibitors Segment by Application
2.4.1 Lung Cancer
2.4.2 Colorectal Cancer
2.4.3 Breast Cancer
2.4.4 Prostate Cancer
2.4.5 Melanoma
2.4.6 Blood Cancer
2.4.7 Other
2.5 Immune Checkpoint Inhibitors Sales by Application
2.5.1 Global Immune Checkpoint Inhibitors Sale Market Share by Application (2019-2024)
2.5.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Application (2019-2024)
2.5.3 Global Immune Checkpoint Inhibitors Sale Price by Application (2019-2024)
3 Global Immune Checkpoint Inhibitors by Company
3.1 Global Immune Checkpoint Inhibitors Breakdown Data by Company
3.1.1 Global Immune Checkpoint Inhibitors Annual Sales by Company (2019-2024)
3.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Company (2019-2024)
3.2 Global Immune Checkpoint Inhibitors Annual Revenue by Company (2019-2024)
3.2.1 Global Immune Checkpoint Inhibitors Revenue by Company (2019-2024)
3.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Company (2019-2024)
3.3 Global Immune Checkpoint Inhibitors Sale Price by Company
3.4 Key Manufacturers Immune Checkpoint Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Checkpoint Inhibitors Product Location Distribution
3.4.2 Players Immune Checkpoint Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Immune Checkpoint Inhibitors by Geographic Region
4.1 World Historic Immune Checkpoint Inhibitors Market Size by Geographic Region (2019-2024)
4.1.1 Global Immune Checkpoint Inhibitors Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Immune Checkpoint Inhibitors Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Immune Checkpoint Inhibitors Market Size by Country/Region (2019-2024)
4.2.1 Global Immune Checkpoint Inhibitors Annual Sales by Country/Region (2019-2024)
4.2.2 Global Immune Checkpoint Inhibitors Annual Revenue by Country/Region (2019-2024)
4.3 Americas Immune Checkpoint Inhibitors Sales Growth
4.4 APAC Immune Checkpoint Inhibitors Sales Growth
4.5 Europe Immune Checkpoint Inhibitors Sales Growth
4.6 Middle East & Africa Immune Checkpoint Inhibitors Sales Growth
5 Americas
5.1 Americas Immune Checkpoint Inhibitors Sales by Country
5.1.1 Americas Immune Checkpoint Inhibitors Sales by Country (2019-2024)
5.1.2 Americas Immune Checkpoint Inhibitors Revenue by Country (2019-2024)
5.2 Americas Immune Checkpoint Inhibitors Sales by Type
5.3 Americas Immune Checkpoint Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Checkpoint Inhibitors Sales by Region
6.1.1 APAC Immune Checkpoint Inhibitors Sales by Region (2019-2024)
6.1.2 APAC Immune Checkpoint Inhibitors Revenue by Region (2019-2024)
6.2 APAC Immune Checkpoint Inhibitors Sales by Type
6.3 APAC Immune Checkpoint Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Immune Checkpoint Inhibitors by Country
7.1.1 Europe Immune Checkpoint Inhibitors Sales by Country (2019-2024)
7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Country (2019-2024)
7.2 Europe Immune Checkpoint Inhibitors Sales by Type
7.3 Europe Immune Checkpoint Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immune Checkpoint Inhibitors by Country
8.1.1 Middle East & Africa Immune Checkpoint Inhibitors Sales by Country (2019-2024)
8.1.2 Middle East & Africa Immune Checkpoint Inhibitors Revenue by Country (2019-2024)
8.2 Middle East & Africa Immune Checkpoint Inhibitors Sales by Type
8.3 Middle East & Africa Immune Checkpoint Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Inhibitors
10.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
10.4 Industry Chain Structure of Immune Checkpoint Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Checkpoint Inhibitors Distributors
11.3 Immune Checkpoint Inhibitors Customer
12 World Forecast Review for Immune Checkpoint Inhibitors by Geographic Region
12.1 Global Immune Checkpoint Inhibitors Market Size Forecast by Region
12.1.1 Global Immune Checkpoint Inhibitors Forecast by Region (2025-2030)
12.1.2 Global Immune Checkpoint Inhibitors Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Immune Checkpoint Inhibitors Forecast by Type
12.7 Global Immune Checkpoint Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Bristol Myer Squibb
13.1.1 Bristol Myer Squibb Company Information
13.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol Myer Squibb Main Business Overview
13.1.5 Bristol Myer Squibb Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Roche / Genentech
13.4.1 Roche / Genentech Company Information
13.4.2 Roche / Genentech Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Roche / Genentech Main Business Overview
13.4.5 Roche / Genentech Latest Developments
13.5 Ono Pharmaceutical
13.5.1 Ono Pharmaceutical Company Information
13.5.2 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Ono Pharmaceutical Main Business Overview
13.5.5 Ono Pharmaceutical Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.7.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Information
13.8.2 Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hengrui Medicine Main Business Overview
13.8.5 Hengrui Medicine Latest Developments
13.9 Junshi Biosciences
13.9.1 Junshi Biosciences Company Information
13.9.2 Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolios and Specifications
13.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Junshi Biosciences Main Business Overview
13.9.5 Junshi Biosciences Latest Developments
14 Research Findings and Conclusion

Table 1. Immune Checkpoint Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Immune Checkpoint Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of PD-1/PD-L1
Table 4. Major Players of CTLA-4
Table 5. Global Immune Checkpoint Inhibitors Sales by Type (2019-2024) & (K Units)
Table 6. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2024)
Table 7. Global Immune Checkpoint Inhibitors Revenue by Type (2019-2024) & ($ million)
Table 8. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2019-2024)
Table 9. Global Immune Checkpoint Inhibitors Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Immune Checkpoint Inhibitors Sales by Application (2019-2024) & (K Units)
Table 11. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2019-2024)
Table 12. Global Immune Checkpoint Inhibitors Revenue by Application (2019-2024)
Table 13. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2019-2024)
Table 14. Global Immune Checkpoint Inhibitors Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Immune Checkpoint Inhibitors Sales by Company (2019-2024) & (K Units)
Table 16. Global Immune Checkpoint Inhibitors Sales Market Share by Company (2019-2024)
Table 17. Global Immune Checkpoint Inhibitors Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Immune Checkpoint Inhibitors Revenue Market Share by Company (2019-2024)
Table 19. Global Immune Checkpoint Inhibitors Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Immune Checkpoint Inhibitors Producing Area Distribution and Sales Area
Table 21. Players Immune Checkpoint Inhibitors Products Offered
Table 22. Immune Checkpoint Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Immune Checkpoint Inhibitors Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Immune Checkpoint Inhibitors Sales Market Share Geographic Region (2019-2024)
Table 27. Global Immune Checkpoint Inhibitors Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Immune Checkpoint Inhibitors Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Immune Checkpoint Inhibitors Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Immune Checkpoint Inhibitors Sales Market Share by Country/Region (2019-2024)
Table 31. Global Immune Checkpoint Inhibitors Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Immune Checkpoint Inhibitors Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Immune Checkpoint Inhibitors Sales by Country (2019-2024) & (K Units)
Table 34. Americas Immune Checkpoint Inhibitors Sales Market Share by Country (2019-2024)
Table 35. Americas Immune Checkpoint Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Immune Checkpoint Inhibitors Revenue Market Share by Country (2019-2024)
Table 37. Americas Immune Checkpoint Inhibitors Sales by Type (2019-2024) & (K Units)
Table 38. Americas Immune Checkpoint Inhibitors Sales by Application (2019-2024) & (K Units)
Table 39. APAC Immune Checkpoint Inhibitors Sales by Region (2019-2024) & (K Units)
Table 40. APAC Immune Checkpoint Inhibitors Sales Market Share by Region (2019-2024)
Table 41. APAC Immune Checkpoint Inhibitors Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Immune Checkpoint Inhibitors Revenue Market Share by Region (2019-2024)
Table 43. APAC Immune Checkpoint Inhibitors Sales by Type (2019-2024) & (K Units)
Table 44. APAC Immune Checkpoint Inhibitors Sales by Application (2019-2024) & (K Units)
Table 45. Europe Immune Checkpoint Inhibitors Sales by Country (2019-2024) & (K Units)
Table 46. Europe Immune Checkpoint Inhibitors Sales Market Share by Country (2019-2024)
Table 47. Europe Immune Checkpoint Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country (2019-2024)
Table 49. Europe Immune Checkpoint Inhibitors Sales by Type (2019-2024) & (K Units)
Table 50. Europe Immune Checkpoint Inhibitors Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Immune Checkpoint Inhibitors Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Immune Checkpoint Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Immune Checkpoint Inhibitors Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Immune Checkpoint Inhibitors Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Immune Checkpoint Inhibitors Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Immune Checkpoint Inhibitors
Table 58. Key Market Challenges & Risks of Immune Checkpoint Inhibitors
Table 59. Key Industry Trends of Immune Checkpoint Inhibitors
Table 60. Immune Checkpoint Inhibitors Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Immune Checkpoint Inhibitors Distributors List
Table 63. Immune Checkpoint Inhibitors Customer List
Table 64. Global Immune Checkpoint Inhibitors Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Immune Checkpoint Inhibitors Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Immune Checkpoint Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Immune Checkpoint Inhibitors Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Immune Checkpoint Inhibitors Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Immune Checkpoint Inhibitors Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Immune Checkpoint Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Immune Checkpoint Inhibitors Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Immune Checkpoint Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Immune Checkpoint Inhibitors Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Immune Checkpoint Inhibitors Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Bristol Myer Squibb Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 80. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Bristol Myer Squibb Main Business
Table 82. Bristol Myer Squibb Latest Developments
Table 83. AstraZeneca Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 85. AstraZeneca Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Merck Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Merck Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 90. Merck Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Merck Main Business
Table 92. Merck Latest Developments
Table 93. Roche / Genentech Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. Roche / Genentech Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 95. Roche / Genentech Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Roche / Genentech Main Business
Table 97. Roche / Genentech Latest Developments
Table 98. Ono Pharmaceutical Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 100. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Ono Pharmaceutical Main Business
Table 102. Ono Pharmaceutical Latest Developments
Table 103. Regeneron Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Regeneron Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 105. Regeneron Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Regeneron Main Business
Table 107. Regeneron Latest Developments
Table 108. Innovent Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Innovent Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 110. Innovent Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Innovent Main Business
Table 112. Innovent Latest Developments
Table 113. Hengrui Medicine Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 115. Hengrui Medicine Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. Hengrui Medicine Main Business
Table 117. Hengrui Medicine Latest Developments
Table 118. Junshi Biosciences Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolios and Specifications
Table 120. Junshi Biosciences Immune Checkpoint Inhibitors Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Junshi Biosciences Main Business
Table 122. Junshi Biosciences Latest Developments
List of

Figure 1. Picture of Immune Checkpoint Inhibitors
Figure 2. Immune Checkpoint Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Checkpoint Inhibitors Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Immune Checkpoint Inhibitors Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Immune Checkpoint Inhibitors Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of PD-1/PD-L1
Figure 10. Product Picture of CTLA-4
Figure 11. Global Immune Checkpoint Inhibitors Sales Market Share by Type in 2023
Figure 12. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2019-2024)
Figure 13. Immune Checkpoint Inhibitors Consumed in Lung Cancer
Figure 14. Global Immune Checkpoint Inhibitors Market: Lung Cancer (2019-2024) & (K Units)
Figure 15. Immune Checkpoint Inhibitors Consumed in Colorectal Cancer
Figure 16. Global Immune Checkpoint Inhibitors Market: Colorectal Cancer (2019-2024) & (K Units)
Figure 17. Immune Checkpoint Inhibitors Consumed in Breast Cancer
Figure 18. Global Immune Checkpoint Inhibitors Market: Breast Cancer (2019-2024) & (K Units)
Figure 19. Immune Checkpoint Inhibitors Consumed in Prostate Cancer
Figure 20. Global Immune Checkpoint Inhibitors Market: Prostate Cancer (2019-2024) & (K Units)
Figure 21. Immune Checkpoint Inhibitors Consumed in Melanoma
Figure 22. Global Immune Checkpoint Inhibitors Market: Melanoma (2019-2024) & (K Units)
Figure 23. Immune Checkpoint Inhibitors Consumed in Blood Cancer
Figure 24. Global Immune Checkpoint Inhibitors Market: Blood Cancer (2019-2024) & (K Units)
Figure 25. Immune Checkpoint Inhibitors Consumed in Other
Figure 26. Global Immune Checkpoint Inhibitors Market: Other (2019-2024) & (K Units)
Figure 27. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2023)
Figure 28. Global Immune Checkpoint Inhibitors Revenue Market Share by Application in 2023
Figure 29. Immune Checkpoint Inhibitors Sales Market by Company in 2023 (K Units)
Figure 30. Global Immune Checkpoint Inhibitors Sales Market Share by Company in 2023
Figure 31. Immune Checkpoint Inhibitors Revenue Market by Company in 2023 ($ Million)
Figure 32. Global Immune Checkpoint Inhibitors Revenue Market Share by Company in 2023
Figure 33. Global Immune Checkpoint Inhibitors Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Immune Checkpoint Inhibitors Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Immune Checkpoint Inhibitors Sales 2019-2024 (K Units)
Figure 36. Americas Immune Checkpoint Inhibitors Revenue 2019-2024 ($ Millions)
Figure 37. APAC Immune Checkpoint Inhibitors Sales 2019-2024 (K Units)
Figure 38. APAC Immune Checkpoint Inhibitors Revenue 2019-2024 ($ Millions)
Figure 39. Europe Immune Checkpoint Inhibitors Sales 2019-2024 (K Units)
Figure 40. Europe Immune Checkpoint Inhibitors Revenue 2019-2024 ($ Millions)
Figure 41. Middle East & Africa Immune Checkpoint Inhibitors Sales 2019-2024 (K Units)
Figure 42. Middle East & Africa Immune Checkpoint Inhibitors Revenue 2019-2024 ($ Millions)
Figure 43. Americas Immune Checkpoint Inhibitors Sales Market Share by Country in 2023
Figure 44. Americas Immune Checkpoint Inhibitors Revenue Market Share by Country in 2023
Figure 45. Americas Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2024)
Figure 46. Americas Immune Checkpoint Inhibitors Sales Market Share by Application (2019-2024)
Figure 47. United States Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 48. Canada Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 49. Mexico Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 50. Brazil Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 51. APAC Immune Checkpoint Inhibitors Sales Market Share by Region in 2023
Figure 52. APAC Immune Checkpoint Inhibitors Revenue Market Share by Regions in 2023
Figure 53. APAC Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2024)
Figure 54. APAC Immune Checkpoint Inhibitors Sales Market Share by Application (2019-2024)
Figure 55. China Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 56. Japan Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 57. South Korea Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 58. Southeast Asia Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 59. India Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 60. Australia Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 61. China Taiwan Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 62. Europe Immune Checkpoint Inhibitors Sales Market Share by Country in 2023
Figure 63. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country in 2023
Figure 64. Europe Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2024)
Figure 65. Europe Immune Checkpoint Inhibitors Sales Market Share by Application (2019-2024)
Figure 66. Germany Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 67. France Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 68. UK Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 69. Italy Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 70. Russia Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 71. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Country in 2023
Figure 72. Middle East & Africa Immune Checkpoint Inhibitors Revenue Market Share by Country in 2023
Figure 73. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2019-2024)
Figure 75. Egypt Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 76. South Africa Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 77. Israel Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 78. Turkey Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 79. GCC Country Immune Checkpoint Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Immune Checkpoint Inhibitors in 2023
Figure 81. Manufacturing Process Analysis of Immune Checkpoint Inhibitors
Figure 82. Industry Chain Structure of Immune Checkpoint Inhibitors
Figure 83. Channels of Distribution
Figure 84. Global Immune Checkpoint Inhibitors Sales Market Forecast by Region (2025-2030)
Figure 85. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted